Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-LARC2 Vaccine in Malaria-Naïve Healthy Adults
NCT06735209Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ-LARC2 in malaria (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Grade 3 laboratory toxicities related to vaccination, Occurrence of serious adverse events (SAEs) considered related to vaccination and 5 more. Started Jul 2025; status: completed.
02
Drugs
PfSPZ-LARC2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06735209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735209.